Drugs / veledimex

Trials 10 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT03679754 Sep 2018 → Apr 2019 glioblastoma Alaunos Therapeutics Completed No outcome recorded
Phase 1 NCT03636477 Jun 2018 → Oct 2020 glioblastoma Alaunos Therapeutics Completed No outcome recorded
Phase 1 NCT02026271 Jun 2015 → Aug 2019 anaplastic oligoastrocytoma, glioblastoma Alaunos Therapeutics Completed No outcome recorded
Phase 1 NCT00815607 Apr 2009 → Jan 2013 melanoma Alaunos Therapeutics Completed No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT03740724 Dec 2019 → Sep 2020 localized scleroderma Castle Creek Biosciences, LLC. Terminated No outcome recorded
Phase 1/2 NCT03330197 Sep 2017 → Sep 2021 diffuse intrinsic pontine glioma Alaunos Therapeutics Terminated No outcome recorded
Phase 1/2 NCT02423902 Jul 2015 → Jul 2016 breast cancer Alaunos Therapeutics Terminated No outcome recorded
Phase 1/2 NCT01397708 Aug 2011 → Sep 2014 melanoma Alaunos Therapeutics Completed No outcome recorded
Phase 22 trials
Phase 2 NCT04006119 Aug 2019 → Aug 2021 glioblastoma Alaunos Therapeutics Terminated No outcome recorded
Phase 2 NCT01703754 Apr 2013 → Aug 2014 breast carcinoma Alaunos Therapeutics Terminated No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as veledimex ClinicalTrials.gov intervention name — accepted as the source's own label NCT03636477
7

NCT03679754

NCT01703754

NCT04006119

NCT02423902

NCT03740724

NCT03330197

NCT02026271

Known as INXN-1001 “evaluating the safety and efficacy of INXN-1001 (veledimex) and INXN-2001 (Ad-RTS-hIL-12) alone and in combination with palifosfamide.” NCT01703754
2

NCT01397708

NCT00815607

Known as RG-115932 ChEMBL registry synonym — accepted as the source's own label CHEMBL3039523
Known as VDX “Veledimex (VDX)-regulatable interleukin-12 (IL-12) gene therapy in recurrent glioblastoma (rGBM) was reported to show tumor infiltration of CD8+ T cells, encouraging survival,...” PMID 34850166 Jun 2022
1

“The oral activator for hIL-12, veledimex (VDX), was administered preoperatively” PMID 31413142 Aug 2019

Action Activate “Oral activator ligand” NCT01703754
Modality Small molecule “Veledimex, is a small molecule which activates the RTS to induce expression of MMP-1” NCT03740724
Route Oral oral Activator Ligand administration” NCT00815607